The National Centre for Pharmacoeconomics reviews the cost-effectiveness and budget impact of individual drugs in the Irish healthcare setting in response to requests from the Department of Health & Children. Evaluations of budget impact analyses have been informed by drug utilisation data extracted from the Community Drugs Schemes databases as appropriate. Evaluations of cost-effectiveness models have been enhanced by the inclusion of Irish cost data as available. Under the terms of the new IPHA/HSE agreement governing reimbursement of drugs in Ireland, effective as of September 1st 2006, the Health Services Executive reserves the right to assess new and existing technologies that may be high cost or have a significant budget impact. In the case of new medicines, assessment may be conducted prior to reimbursement but must be completed within 90 days of the reimbursement application. Evaluations will be conducted in accordance with the existing Irish Healthcare Technology Assessment (HTA) Guidelines and due to the time constraint will of necessity comprise rapid HTA.                                                 

Completed Evaluations: